

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB 5/24/1952
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Bladder Cancer FISH Final Report (Refer to test 3016627)

ARUP test code 3016628

Clinical History	Clinical Information: No clinical information provided.
Bladder Cancer FISH Specimen Source	Urine
Fixative	PreservCyt
Gross Description	Received 85 mL fluid in PreservCyt
Comments	<p>This test has been scanned by the Bioview automated slide screener and reviewed by the pathologist (CPT 88121).</p> <p>Controls performed as expected.</p> <p>TC:164</p> <p>ISCN: nuc ish(CEP3,CEP7,9p21,CEP17)x2</p>

H=High, L=Low, *=Abnormal, C=Critical

Interpretation

Negative: No evidence of numeric chromosomal aberrations associated with urothelial carcinoma identified.

Negative results indicate a lack of evidence for the presence of numeric chromosomal abnormalities commonly associated with urothelial carcinoma, within the cells collected in this specimen. Negative results in the presence of other symptoms/signs of urothelial carcinoma may suggest the possibility of a false-negative test. In this circumstance, additional clinical studies to exclude urothelial carcinoma should be pursued, as clinically indicated. Although this test was designed to detect genetic abnormality associated with most urothelial cancers, there will be some urothelial cancers whose genetic changes cannot be detected by this test.

The UroVysion Bladder Cancer Kit probes were used to detect aneuploidy for chromosomes 3, 7, 17 and/or loss of 9p21 locus via fluorescence in situ hybridization (FISH). Results from this test are intended for use in conjunction with, and not in lieu of, current standard diagnostic procedures, as an aid for initial diagnosis of urothelial carcinoma and for monitoring for tumor recurrence in conjunction with cystoscopy in patients with previously diagnosed bladder cancer.

01/15/25 Reviewed by: [REDACTED]

01/16/25 Verified By: [REDACTED]
electronic signature

I certify that I personally conducted the evaluation on the above specimen(s) and have rendered the above interpretation(s).

[REDACTED]

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Clinical History	BC-250-000864	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Bladder Cancer FISH Specimen Source	BC-250-000864	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Fixative	BC-250-000864	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Gross Description	BC-250-000864	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Comments	BC-250-000864	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Interpretation	BC-250-000864	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical